Anomalies pigmentaires induites par les traitements anticancéreux. Première partie : les chimiothérapies

Sibaud, Vincent; Fricain, Jean-Christophe; Baran, Robert; Robert, Caroline

doi:10.1016/j.annder.2012.12.012

Cited by 34 publications

(11 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Imaging features were consistent with histopathological findings previously described [1,2,3,4,5,6], i.e. suggestive of a stimulation of melanogenesis with an increased content of melanin in basal keratinocytes.…”

Section: Discussionsupporting

confidence: 75%

“…Electron microscopic analysis confirmed an increased number of melanosomes in basal keratinocytes associated with mitochondrial damage, suggesting a local toxic effect. In fact, as in our 2 biopsied patients, the histopathological changes were similar to those chiefly observed in other chemotherapy-related pigmentary changes and evoking increased melanogenesis in response to direct damage to epidermal cells [1,2,5,6,8,9,10]. The 3 other remaining case reports were also clinically similar to our patients, but skin biopsies were not performed in any of the latter cases.…”

Section: Discussionsupporting

confidence: 56%

“…Although available histopathological or ultrastructural studies remain scarce, the most frequent patterns suggest a direct toxic effect on melanocytes, inducing melanogenesis stimulation and a marked increase of epidermal melanin production, with a secondary accumulation in keratinocytes and the upper dermis or into melanophages. In addition, an increased number of melanosomes in keratinocytes, with a normal range of melanocytes [1,5,6,7,8,9,10], has been identified. …”

Section: Introductionmentioning

confidence: 99%

“…Chemotherapy-induced pigmentary changes represent a well-recognized complication of cancer treatment [1,2,3,4,5,6]. They may involve the skin, hair or nails and a number of chemotherapeutic agents can predispose to the development of these lesions.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature

Regnault

Gadaud²,

Boulinguez

et al. 2015

Dermatology

View full text Add to dashboard Cite

Background: Inherited or acquired reticulate hyperpigmentation represents a heterogeneous group of infrequent dermatological conditions. The development of reticulate hyperpigmentation has so far been rarely reported to be associated with chemotherapeutic agents, including fluorouracil, bleomycin or a combination of cytarabine and idarubicin. Case Reports: We describe 5 cases of chemotherapy-related reticulate hyperpigmentation in patients treated with different chemotherapeutic regimens, in particular paclitaxel or cytarabine. The lesions were similar in all cases, with reticulate and/or linear hyperpigmented streaks, which were mainly located to the back and buttocks. Histology showed increased melanogenesis, which suggests a direct toxic effect of chemotherapy on melanocytes. Reflectance confocal microscopy was performed in 2 patients showing a similar pattern, with an increased amount of melanin in basal keratinocytes. These features have been compared with the available data through a literature review. Conclusion: Reticulate hyperpigmentation is an underestimated but characteristic complication of chemotherapy. Neither specific management nor discontinuation of the chemotherapeutic regimen is required.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionsupporting

confidence: 56%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature

Regnault

Gadaud²,

Boulinguez

et al. 2015

Dermatology

View full text Add to dashboard Cite

show abstract

“…C'est un des effets indésirables cutané les plus fréquem-ment observés avec les anticancéreux [95]. L'hyperpigmentation peut apparaître d'emblée ou correspondre à une pigmentation post-inflammatoire.…”

Section: Pigmentations Cutanéesunclassified

Toxidermies

Lebrun‐Vignes

Valeyrie‐Allanore

2015

La Revue de Médecine Interne

View full text Add to dashboard Cite

Cutaneous adverse drug reactions (CADR) represent a heterogeneous field including various clinical patterns without specific features suggesting drug causality. Exanthematous eruptions, urticaria and vasculitis are the most common forms of CADR. Fixed eruption is uncommon in western countries. Serious reactions (fatal outcome, sequelae) represent 2% of CADR: bullous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), DRESS (drug reaction with eosinophilia and systemic symptoms or drug-induced hypersensitivity syndrome) and acute generalized exanthematous pustulosis (AGEP). These forms must be quickly diagnosed to guide their management. The main risk factors are immunosuppression, autoimmunity and some HLA alleles in bullous reactions and DRESS. Most systemic drugs may induce cutaneous adverse reactions, especially antibiotics, anticonvulsivants, antineoplastic drugs, non-steroidal anti-inflammatory drugs, allopurinol and contrast media. Pathogenesis includes immediate or delayed immunologic mechanism, usually not related to dose, and pharmacologic/toxic mechanism, commonly dose-dependent or time-dependent. In case of immunologic mechanism, allergologic exploration is possible to clarify drug causality, with a variable sensitivity according to the drug and to the CADR type. It includes epicutaneous patch testing, prick test and intradermal test. However, no in vivo or in vitro test can confirm the drug causality. To determine the cause of the eruption, a logical approach based on clinical characteristics, chronologic factors and elimination of differential diagnosis is required, completed with a literature search. A reporting to pharmacovigilance network is essential in case of a serious CADR whatever the suspected drug and in any case if the involved drug is a newly marketed one or unusually related to cutaneous reactions.

show abstract

Common Cutaneous Side Effects of Anti-cancer Agents

Zarbo

Axelson

2019

Practical Guide to Dermatology

View full text Add to dashboard Cite

Anomalies pigmentaires induites par les traitements anticancéreux. Première partie : les chimiothérapies

Cited by 34 publications

References 117 publications

Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature

Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature

Toxidermies

Common Cutaneous Side Effects of Anti-cancer Agents

Contact Info

Product

Resources

About